Skip Navigation

Adalvo acquires its first branded product, Onsolis®

02 August 2022

Adalvo is thrilled to announce the acquisition of our first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, who originally owned the product.

The brand is an opioid analgesic, indicated in the management of persistent breakthrough pain, in cancer patients who have already received and are tolerant to opioid therapy for their underlying cancer pain. Adalvo will be the sole and exclusive owner of the brand and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.

The brand is being sold in several EU countries and in Taiwan by business partners. Adalvo will assume the supply responsibility and business continuity for these partners.

Anil Okay, CEO at Adalvo, comments: “This acquisition paves the way towards a transformative journey, at Adalvo. It is a real game changer, and we are thrilled to be venturing into the branded product domain, growing our position as a global partner of choice”.

Our business remains fueled by our passion for relentless commitment to the partner network that we serve, and we will continue to bring high value assets to our portfolio, now venturing also within the branded product domain.